Jan 20 (Reuters) – Novavax said on Tuesday it has entered into a licensing agreement with Pfizer to develop vaccine products for infectious diseases. Pfizer will gain access to Novavax's Matrix-MT adjuvant technology and have control over all matters relating to the development, manufacture and commercialization of any products that contain the adjuvant, apart from its delivery and supply. Novavax said it will receive an upfront payment of $30 million in the first quarter of 2026, and be eligible to receive up to an additional $500 million in milestone payments. Shares of Novavax climbed 2% in premarket trading. (Reporting by Christy Santhosh in Bengaluru; Editing by Shinjini Ganguli)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
